Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Hull University Teaching Hospitals NHS Trust, Hull, UK.
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.
Risk of adverse effects and flare of inflammatory bowel disease (IBD) are frequently cited reasons for COVID-19 vaccine hesitancy.
Electronic databases were searched to identify studies reporting the use of COVID-19 vaccine in IBD. We selected studies reporting the incidence of various adverse effects (local or systemic) and flares of IBD after COVID-19 vaccination. The pooled incidence rates for various adverse effects, stratified for the dose and the type of vaccine (adenoviral or mRNA) were estimated.
Nine studies (16 vaccination cohorts) were included. The pooled incidence rate of overall adverse events was 0.55 (95%CI, 0.45-0.64, I= 95%). The pooled incidence rate of local adverse events was 0.64 (0.47-0.78, I= 100%). The pooled incidence rates of fatigue, headache, myalgia, fever and chills were 0.30 (0.21-0.40, I= 99%), 0.23 (0.17-0.30, I= 99%), 0.18 (0.13-0.24, I= 99%), 0.10 (0.06-0.17, I= 98%) and 0.15 (0.06-0.3, I= 86%), respectively. The pooled incidence rates of severe adverse events, adverse events requiring hospitalization and flares of IBD following COVID-19 vaccination were 0.02 (0.00-0.12, I= 97%), 0.00 (0.00-0.01, I= 27%) and 0.01 (0.01-0.03, I= 45%), respectively.
COVID-19 vaccination in patients with IBD appears to be safe with only mild adverse events. Flares of IBD and severe adverse events requiring hospitalization were infrequent.
不良影响和炎症性肠病（IBD）发作的风险经常被认为是 COVID-19 疫苗犹豫的原因。
电子数据库被搜索以确定报告 COVID-19 疫苗在 IBD 中应用的研究。我们选择报告 COVID-19 疫苗接种后各种不良影响（局部或全身）和 IBD 发作发生率的研究。估计了各种不良影响的合并发生率，分为剂量和疫苗类型（腺病毒或 mRNA）。
共纳入 9 项研究（16 个疫苗队列）。总体不良事件的合并发生率为 0.55（95%CI，0.45-0.64，I=95%）。局部不良事件的合并发生率为 0.64（0.47-0.78，I=100%）。疲劳、头痛、肌痛、发热和寒战的合并发生率分别为 0.30（0.21-0.40，I=99%）、0.23（0.17-0.30，I=99%）、0.18（0.13-0.24，I=99%）、0.10（0.06-0.17，I=98%）和 0.15（0.06-0.3，I=86%）。COVID-19 疫苗接种后严重不良事件、需要住院的不良事件和 IBD 发作的合并发生率分别为 0.02（0.00-0.12，I=97%）、0.00（0.00-0.01，I=27%）和 0.01（0.01-0.03，I=45%）。
在 IBD 患者中 COVID-19 疫苗接种似乎是安全的，仅有轻度不良事件。IBD 发作和需要住院的严重不良事件较为少见。
